FLT3 and acute myeloid leukemia: In the relapsed/refractory setting, patients with FLT3-ITD-positive AML receiving TKI monotherapy showed promising outcomes (14–16), while this approach may remain a palliative strategy which is furthermore limited by emerging TKI resistance (17, 18).